Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2024 · View financials
Decision snapshot: INFY stock price vs ZNTL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZNTL's multiple
Needs ZNTL P/E.
Implied fair value · at INFY's multiple
Needs EPS (TTM) is negative, INFY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INFY FY 2025 (ended Mar 31, 2025) · ZNTL FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
INFOSYS LIMITED · implied price per share
Bear
$3.82
Base
$4.49
Bull
$5.17
Zentalis Pharmaceuticals, Inc. · implied price per share
Bear
-$2.26
Base
-$2.66
Bull
-$3.06
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
0.29x
Net debt / EBITDA
Leverage against operating earnings
0.98x
-0.19x
Cash and equivalents
Liquid reserves on the balance sheet
$2.86B
$36.00M
Total debt
Interest-bearing obligations outstanding
$5.96B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Accenture plc
INFY vs ACN
COGNIZANT TECHNOLOGY SOLUTIONS CORP
INFY vs CTSH
INTERNATIONAL BUSINESS MACHINES CORP
INFY vs IBM
DXC Technology Co
INFY vs DXC
Arcus Biosciences, Inc.
INFY vs RCUS
Repare Therapeutics Inc.
INFY vs RPTX
IDEAYA Biosciences, Inc.
INFY vs IDYA
Mersana Therapeutics, Inc.
INFY vs MRSN
EXELIXIS, INC.
INFY vs EXEL
$61.78M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
